Resultados de Búsqueda por Autor

1

revisión

The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer

Publicado por
Motta-Guerrero, R, Recondo, G, Cardona, A, Corrales, L, Arnao, V, Failoc-Rojas, VE, Aliaga, C

Publicado 2024

Enlace

Tyrosine kinase inhibitors (TKIs) are the standard treatment for epidermal growth factor receptor mutant (EGFRm) advanced non-small cell lung cancer (NSCLC). Combining TKIs with an angiogenesis inhibitor has shown promise in pre-clinical studies. A systematic search of clinical trials found that combining erlotinib (a first-generation TKI) with bevacizumab or ramucirumab (angiogenesis inhibitors) improved progression-free survival (PFS) in EGFRm advanced NSCLC patients compared to TKI alone. However, no significant benefit in overall survival (OS) was observed in trials. Similar efficacy was seen in patients with specific EGFR mutations. Third generation TKIs were used as second-line therapy for patients with the T790M mutation. The combination treatment was associated with a higher incidence of severe adverse events. Overall, combining erlotinib or another TKI with an angiogenesis inhib...

2

artículo

Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protoco...

Publicado por
Raez, LE, Arrieta, O, Chamorro, DF, Soberanis-Piña, PD, Corrales, L, Martín, C, Cuello, M, Samtani, S, Recondo, G, Mas López, L, Zatarain-Barrón, ZL, Ruíz-Patiño, A, García-Robledo, JE, Ordoñez-Reyes, C, Jaller, E, Dickson, F, Rojas, L, Rolfo, C, Rosell, R, Cardona, AF

Publicado 2022

Enlace

Objectives: To compare the rate disparity between outcomes (overall survival (OS), progression-free survival (PFS), and safety) of concurrent chemoradiation (cCRT) followed by durvalumab in two patient cohorts with locally advanced (LA) stage III non-small cell lung cancer (NSCLC), one non-Hispanic White (NHW), and the other Latin-American. Methods: A multicenter retrospective study was performed, including 80 Hispanic and 45 NHW LA stage III NSCLC patients treated with cCRT followed by durvalumab. Both cohorts were analyzed in terms of main outcomes (OS, PFS, and safety) and compared between them and with the PACIFIC trial population outcomes. The efficacy-effectiveness gap was assessed using an efficacy-effectiveness (EE) factor that was calculated by dividing each cohort median overall survival by the corresponding reference OS from the PACIFIC trial. In both cohorts, results of PD-L1...

3

artículo

STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)

Publicado por
Cordeiro de Lima, VC, Corassa, M, Saldanha, E, Freitas, H, Arrieta, O, Raez, L, Samtani, S, Ramos, M, Rojas, C, Burotto, M, Chamorro, DF, Recondo, G, Ruiz-Patiño, A, Más López, L, Zatarain-Barrón, L, Mejía, S, Nicolas Minata, J, Martín, C, Bautista Blaquier, J, Motta Guerrero, R, Aliaga-Macha, C, Carracedo-Gonzales, C, Ordóñez-Reyes, C, Garcia-Robledo, JE, Corrales, L, Sotelo, C, Ricaurte, L, Santoyo, N, Cuello, M, Jaller, E, Rodríguez, J, Archila, P, Bermudez, M, Gamez, T, Russo, A, Viola, L, Malapelle, U, de Miguel Perez, D, Rolfo, C, Rosell, R, Cardona, AF

Publicado 2022

Enlace

Background: Mutations in STK11 (STK11Mut) and, frequently co-occurring, KEAP1 mutations (KEAP1Mut) are associated with poor survival in metastatic Non-small Cell Lung Cancer (mNSCLC) patients treated with immunotherapy. However, there are limited data regarding the prognostic or predictive significance of these genomic alterations among Hispanics. Methods: This retrospective study analyzed a cohort of Hispanic patients (N = 103) diagnosed with mNSCLC from the US and seven Latin American countries (LATAM) treated with immune checkpoint inhibitors (ICI) alone or in combination as first-line (Cohort A). All cases were treated in routine care between January 2016 and December 2021. The main objectives were to determine the association of mutations in STK11 or KEAP1 in these patients’ tumors with overall (OS) and progression-free survival (PFS), presence of KRAS mutations, tumor mutational ...